Eli Lilly Announces Leadership Changes

Lilly last month detailed plans to invest $850 million into its U.S. operations this year.

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced several changes to the company’s executive committee. The company says the changes involve two senior vice presidents.

Mike Harrington is retiring from his positions of senior vice president and general counsel at the end of the year. Senior vice president and president of Lilly Bio-medicines, Christi Shaw, is leaving Lilly at the end of August, and will be succeeded by current president and general manager of Lilly Japan, Patrick Jonsson.

Shaw served as president of Novartis USA and North American region head of Novartis Oncology, and held roles with Johnson & Johnson in the 2000’s. She returned to Lilly in 2017.

Harrington has been on Lilly’s executive committee for seven years.

"Thanks to Mike’s leadership, the company maintained patent exclusivity for a number of important medicines, including Alimta®, completed the Elanco divestiture and finalized acquisitions such as Loxo Oncology and ARMO BioSciences," said David A. Ricks, Lilly’s chairman and CEO. 

The company is currently searching for Harrington’s replacement.